CureVac N.V.
CVAC
Cena:
$ 4.66
0.00 (0.00%)
Valuace
83
Růst
70
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
BIONTECH ACHIEVES MINIMUM CONDITION IN CUREVAC EXCHANGE OFFER
03-12-2025
THE MINIMUM CONDITION FOR THE OFFER HAS BEEN SATISFIED, WITH 184,071,410 SHARES OF CUREVAC, REPRESEN...
Více zde
CUREVAC ANNOUNCES VOTING RESULTS OF EXTRAORDINARY GENERAL MEETING
25-11-2025
TÜBINGEN, DE AND BOSTON, MA / ACCESS NEWSWIRE / NOVEMBER 25, 2025 / CUREVAC N.V. (NASDAQ:CVAC)(CURE...
Více zde
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2025 AND PROVIDES BUSINESS UPDATES
24-11-2025
GERMAN FEDERAL CARTEL OFFICE CLEARANCE OBTAINED FOR THE PLANNED BIONTECH - CUREVAC TRANSACTION ANNOU...
Více zde
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2025 AND PROVIDES BUSINESS UPDATES
15-08-2025
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2025 AND PROVIDES BUSIN...
Více zde
CUREVAC ANNOUNCES VOTING RESULTS OF GENERAL MEETING
24-06-2025
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / JUNE 24, 2025 / CUREVAC N.V. (NASDAQ:CVAC), A ...
Více zde
$HAREHOLDER ALERT: CLASS ACTION ATTORNEY JUAN MONTEVERDE INVESTIGATES THE MERGER OF CUREVAC N.V. (NASDAQ: CVAC)
20-06-2025
NEW YORK, JUNE 20, 2025 (GLOBE NEWSWIRE) -- CLASS ACTION ATTORNEY JUAN MONTEVERDE WITH MONTEVERDE & ...
Více zde
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES CVAC, KNW, SOAR, HLGN ON BEHALF OF SHAREHOLDERS
13-06-2025
NEW YORK, JUNE 13, 2025 (GLOBE NEWSWIRE) -- HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVEST...
Více zde
CVAC STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF CUREVAC N.V. IS FAIR TO SHAREHOLDERS
12-06-2025
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025 AND PROVIDES BUSINESS UPDATES
20-05-2025
U.S. FDA CLEARS LUNG CANCER IND FOR CVHNLC, A PROPRIETARY OFF-THE-SHELF CANDIDATE TARGETING SQUAMOUS...
Více zde
CUREVAC RECEIVES ADDITIONAL POSITIVE VALIDITY DECISION FROM EUROPEAN PATENT OFFICE IN ONGOING LITIGATION AGAINST BIONTECH SE
15-05-2025
EUROPEAN PATENT OFFICE LARGELY DISMISSES OPPOSITION FILED BY BIONTECH SE, PFIZER INC., AND OTHERS IN...
Více zde
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2024 AND PROVIDES BUSINESS UPDATE
10-04-2025
STRATEGIC MILESTONE ACHIEVEMENT AND INCREASED FINANCIAL DISCIPLINE UNDERSCORE YEAR OF CORPORATE TRAN...
Více zde
CUREVAC TO REPORT FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATE ON APRIL 10, 2025
08-04-2025
TÜBINGEN, DE / ACCESS NEWSWIRE / APRIL 8, 2025 / CUREVAC N.V. (NASDAQ:CVAC) ("CUREVAC"), A GLOBAL B...
Více zde
CUREVAC RECEIVES U.S. FDA IND CLEARANCE TO INITIATE PHASE 1 CLINICAL TRIAL FOR NOVEL MRNA-BASED PRECISION IMMUNOTHERAPY IN SQUAMOUS NON-SMALL CELL LUNG CANCER
07-04-2025
SIGNIFICANT REGULATORY MILESTONE: U.S. FDA CLEARED IND APPLICATION FOR CVHNLC, CUREVAC'S INVESTIGATI...
Více zde
CUREVAC RECEIVES POSITIVE VALIDITY DECISION FROM EUROPEAN PATENT OFFICE IN LITIGATION AGAINST BIONTECH SE
27-03-2025
EUROPEAN PATENT OFFICE LARGELY DISMISSES OPPOSITION FILED BY BIONTECH SE IN APRIL 2023 CHALLENGING V...
Více zde
CUREVAC EARNS REPEAT RECOGNITION BY LEXISNEXIS(R) AS ONE OF THE WORLD'S TOP INNOVATORS
18-02-2025
CUREVAC AMONG GLOBAL TOP 100 MOST FAST-PACED INNOVATORS FOR THIRD CONSECUTIVE YEAR IN ACKNOWLEDGMENT...
Více zde
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2024 AND PROVIDES BUSINESS UPDATE
12-11-2024
STRENGTHENED CASH, STRATEGIC REFOCUS AND PIPELINE PROGRESS DEFINE TRANSFORMATIVE QUARTER €400 MILL...
Více zde
CUREVAC TO REPORT THIRD QUARTER AND FIRST NINE MONTHS 2024 FINANCIAL RESULTS AND BUSINESS UPDATE ON NOVEMBER 12, 2024
07-11-2024
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / NOVEMBER 7, 2024 / CUREVAC N.V. (NASDAQ:CVAC) ("CUR...
Více zde
CUREVAC STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF SEASONED INDUSTRY EXECUTIVE AXEL SVEN MALKOMES AS CHIEF FINANCIAL OFFICER
04-11-2024
EXPERIENCED CFO AND INVESTMENT BANKER WITH 30-YEAR TRACK RECORD WILL HELP DRIVE CUREVAC'S TRANSFORMA...
Více zde
CUREVAC TO PRESENT AT THE 12TH INTERNATIONAL MRNA HEALTH CONFERENCE
04-11-2024
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / NOVEMBER 4, 2024 / CUREVAC N.V. (NASDAQ:CVAC) ("CUR...
Více zde
CUREVAC TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING
28-10-2024
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / OCTOBER 28, 2024 / CUREVAC N.V. (NASDAQ:CVAC) ("CUR...
Více zde
CUREVAC'S CVGBM CANCER VACCINE INDUCES PROMISING IMMUNE RESPONSES IN PHASE 1 STUDY IN GLIOBLASTOMA PRESENTED AT THE ESMO 2024 CONGRESS
13-09-2024
PRELIMINARY IMMUNOGENICITY RESULTS DEMONSTRATE INDUCTION OF CANCER ANTIGEN-SPECIFIC T-CELL RESPONSES...
Více zde
CUREVAC PARTNER GSK ANNOUNCES POSITIVE PHASE 2 DATA FROM SEASONAL INFLUENZA MRNA VACCINE PROGRAM
12-09-2024
PHASE 2 DATA DEMONSTRATED POSITIVE IMMUNE RESPONSES TO A AND B STRAINS, WITH ACCEPTABLE SAFETY AND R...
Více zde
CUREVAC TO PRESENT FIRST CVGBM GLIOBLASTOMA CANCER VACCINE CLINICAL DATA AT ESMO 2024 CONGRESS
09-09-2024
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / SEPTEMBER 9, 2024 / CUREVAC N.V. (NASDAQ:CVAC) ("CU...
Více zde
CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2024 AND PROVIDES BUSINESS UPDATE
15-08-2024
CLOSED NEW LICENSING AGREEMENT WITH GSK WORTH UP TO €1.45 BILLION, INCLUDING €400 MILLION UPFRON...
Více zde
CUREVAC ADVANCES CANCER VACCINE CANDIDATE CVGBM TO PART B OF PHASE 1 STUDY IN PATIENTS WITH RESECTED GLIOBLASTOMA
15-08-2024
FIRST PATIENT ADMINISTERED IN DOSE-CONFIRMATION PART B OF PHASE 1 STUDY WITH MRNA-BASED, MULTIEPITOP...
Více zde
CUREVAC NAMES ONCOLOGIST AND DRUG DEVELOPMENT EXPERT DR. MEHDI SHAHIDI TO SUPERVISORY BOARD
15-08-2024
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / AUGUST 15, 2024 / CUREVAC N.V. (NASDAQ:CVAC) ("CURE...
Více zde
CUREVAC PROVIDES UPDATE ON TRIAL DATES FOR PATENT LITIGATION ACROSS MULTIPLE GEOGRAPHIES AGAINST PFIZER/BIONTECH
11-07-2024
NEW TRIAL DATE FOR U.S. PATENT LITIGATION SET FOR MARCH 3, 2025, FOLLOWING SETTLEMENT WITH ACUITAS T...
Více zde
AGOMAB BOLSTERS EXECUTIVE TEAM WITH APPOINTMENT OF PIERRE KEMULA AS CHIEF FINANCIAL OFFICER
11-07-2024
ANTWERP, BELGIUM--(BUSINESS WIRE)--AGOMAB THERAPEUTICS NV (‘AGOMAB') TODAY ANNOUNCED THAT PIERRE K...
Více zde
CUREVAC INITIATES STRATEGIC RESTRUCTURING TO ALIGN RESOURCES WITH FOCUS ON HIGH-VALUE MRNA PIPELINE OPPORTUNITIES
03-07-2024
STRATEGIC RESTRUCTURING INCLUDES A WORKFORCE REDUCTION OF APPROXIMATELY 30%, RE-FOCUSING ON RESEARCH...
Více zde
CUREVAC ANNOUNCES VOTING RESULTS OF GENERAL MEETING
24-06-2024
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / JUNE 24, 2024 / CUREVAC N.V. (NASDAQ:CVAC), A GLOBA...
Více zde
Dokumenty nejsou k dispozici
